SG190244A1 - Methods of treating cancer - Google Patents
Methods of treating cancer Download PDFInfo
- Publication number
- SG190244A1 SG190244A1 SG2013036280A SG2013036280A SG190244A1 SG 190244 A1 SG190244 A1 SG 190244A1 SG 2013036280 A SG2013036280 A SG 2013036280A SG 2013036280 A SG2013036280 A SG 2013036280A SG 190244 A1 SG190244 A1 SG 190244A1
- Authority
- SG
- Singapore
- Prior art keywords
- chemotherapeutic agent
- inhibition
- weeks
- additional chemotherapeutic
- kit
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Inorganic Chemistry (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Reproductive Health (AREA)
- Food Science & Technology (AREA)
- Pulmonology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41327510P | 2010-11-12 | 2010-11-12 | |
| PCT/US2011/060407 WO2012065085A1 (en) | 2010-11-12 | 2011-11-11 | Methods of treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG190244A1 true SG190244A1 (en) | 2013-06-28 |
Family
ID=46048353
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2013036280A SG190244A1 (en) | 2010-11-12 | 2011-11-11 | Methods of treating cancer |
| SG2013036306A SG190245A1 (en) | 2010-11-12 | 2011-11-11 | Methods of treating cancer |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2013036306A SG190245A1 (en) | 2010-11-12 | 2011-11-11 | Methods of treating cancer |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US8987281B2 (https=) |
| EP (2) | EP2638395A4 (https=) |
| JP (2) | JP2013542263A (https=) |
| KR (2) | KR20130140032A (https=) |
| CN (2) | CN103282777A (https=) |
| AU (2) | AU2011325989C1 (https=) |
| BR (2) | BR112013011590A2 (https=) |
| CA (2) | CA2817223A1 (https=) |
| CL (2) | CL2013001324A1 (https=) |
| EA (2) | EA026168B1 (https=) |
| IL (2) | IL226247A0 (https=) |
| MX (2) | MX2013005196A (https=) |
| SG (2) | SG190244A1 (https=) |
| WO (2) | WO2012065085A1 (https=) |
| ZA (2) | ZA201304226B (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101098854B (zh) | 2004-07-23 | 2012-12-05 | 恩多塞特公司 | 二价连接体及其轭合物 |
| US9877965B2 (en) | 2007-06-25 | 2018-01-30 | Endocyte, Inc. | Vitamin receptor drug delivery conjugates for treating inflammation |
| CN101784565B (zh) | 2007-06-25 | 2014-12-10 | 恩多塞特公司 | 含有亲水性间隔区接头的共轭物 |
| KR20130140032A (ko) | 2010-11-12 | 2013-12-23 | 엔도사이트, 인코포레이티드 | 암을 치료하는 방법들 |
| SG194458A1 (en) * | 2011-04-12 | 2013-12-30 | Endocyte Inc | Solid pharmaceutical composition |
| US10080805B2 (en) | 2012-02-24 | 2018-09-25 | Purdue Research Foundation | Cholecystokinin B receptor targeting for imaging and therapy |
| US20140154702A1 (en) * | 2012-11-30 | 2014-06-05 | Endocyte, Inc. | Methods For Treating Cancer Using Combination Therapies |
| WO2015077303A1 (en) | 2013-11-19 | 2015-05-28 | Purdue Research Foundation | Patient selection method for inflammation |
| KR102410090B1 (ko) | 2014-02-21 | 2022-06-16 | 넥타르 테라퓨틱스 (인디아) 프라이빗 리미티드 | 항-ｃｔｌａ－４ 항체 또는 항-ｐｄ－１ 항체와 조합한 ｉｌ－２ｒ베타-선택적 효현제 |
| CN103816548A (zh) * | 2014-03-11 | 2014-05-28 | 北京林业大学 | 靶向亲水性聚合物-雷公藤甲素结合物 |
| SG11201608303QA (en) | 2014-04-04 | 2016-11-29 | Del Mar Pharmaceuticals | Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer |
| WO2015160833A1 (en) * | 2014-04-14 | 2015-10-22 | Endocyte, Inc. | Drug delivery conjugates for treating resistant cancer and for use in combination therapy |
| CN112638363B (zh) * | 2018-08-31 | 2025-01-24 | 太阳医药工业有限公司 | 卡铂的肠胃外剂型 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6441026B1 (en) * | 1993-11-08 | 2002-08-27 | Aventis Pharma S.A. | Antitumor compositions containing taxane derivatives |
| CA2484640C (en) * | 2002-05-15 | 2012-01-17 | Endocyte, Inc. | Vitamin-mitomycin conjugates |
| US20060024692A1 (en) | 2002-09-30 | 2006-02-02 | Oncotherapy Science, Inc. | Method for diagnosing non-small cell lung cancers |
| WO2004069159A2 (en) * | 2003-01-27 | 2004-08-19 | Endocyte, Inc. | Vitamin receptor binding drug delivery conjugates |
| CN101239190B (zh) * | 2003-01-27 | 2013-09-25 | 恩多塞特公司 | 维生素受体结合递药缀合物 |
| ATE460668T1 (de) * | 2005-03-30 | 2010-03-15 | Purdue Research Foundation | Verfahren zur prognose von brustkrebs mittels quantifizierung von zellulären folat vitamin rezeptoren |
| EP2382995A3 (en) * | 2005-08-19 | 2013-09-25 | Endocyte, Inc. | Ligand conjugates of Vinca alkaloids, analogs and derivatives |
| US20070065449A1 (en) | 2005-09-16 | 2007-03-22 | Claire Verschraegen | Method of treating cancer, especially soft tissue sarcoma utilizing gemcitabine in combination with docetaxel and anti-VEGF therapy (bevacizumab) |
| CN101784565B (zh) | 2007-06-25 | 2014-12-10 | 恩多塞特公司 | 含有亲水性间隔区接头的共轭物 |
| ES3029483T3 (en) * | 2008-09-17 | 2025-06-24 | Endocyte Inc | Folate receptor binding conjugates of antifolates |
| WO2010056337A2 (en) * | 2008-11-12 | 2010-05-20 | Caris Mpi, Inc. | Methods and systems of using exosomes for determining phenotypes |
| BR112012002064A2 (pt) | 2009-07-31 | 2017-05-09 | Endocyte Inc | método para determinar se ec145 é indicado para o tratamento de um paciente com um tumor ovariano ou um tumor de pulmão; método para prever uma resposta de um tumor ovariano ou um tumor de pulmão de um paciente a terapia com ec145; método de tratamento de câncer ovariano resistente à platina em um paciente necessitando dele; uso de ec145 em combinação com doxorrubicina lipossômica peguilada; uso de ec145 para a fabricação de um medicamento; método para obter um benefício clínico comparado a tratamento com uma quantidade terapêutica de doxorrubicina lipossômica peguilada no tratamento de câncer ovariano resistente à platina em um paciente necessitando dele; método para selecionar um paciente para tratamento; composição farmacêutica; unidade de dosagem, método para determinar se um paciente com um tumor tem receptores de folato funcionalmente ativos presentes no tumor do paciente; método de tratamento de um tumor epitelial expressando receptor de folato em um paciente necessitando dele; e; método para obter um benefício clínico no tratamento de um tumor epitelial expressando receptor de folato em um paciente necessitando dele |
| KR20130140032A (ko) | 2010-11-12 | 2013-12-23 | 엔도사이트, 인코포레이티드 | 암을 치료하는 방법들 |
-
2011
- 2011-11-11 KR KR1020137013270A patent/KR20130140032A/ko not_active Ceased
- 2011-11-11 KR KR1020137013272A patent/KR20130140033A/ko not_active Ceased
- 2011-11-11 BR BR112013011590-4A patent/BR112013011590A2/pt not_active IP Right Cessation
- 2011-11-11 US US13/294,624 patent/US8987281B2/en not_active Expired - Fee Related
- 2011-11-11 CA CA2817223A patent/CA2817223A1/en not_active Abandoned
- 2011-11-11 CN CN2011800634321A patent/CN103282777A/zh active Pending
- 2011-11-11 AU AU2011325989A patent/AU2011325989C1/en not_active Ceased
- 2011-11-11 EA EA201390695A patent/EA026168B1/ru not_active IP Right Cessation
- 2011-11-11 JP JP2013538937A patent/JP2013542263A/ja active Pending
- 2011-11-11 EP EP11839397.4A patent/EP2638395A4/en not_active Withdrawn
- 2011-11-11 WO PCT/US2011/060407 patent/WO2012065085A1/en not_active Ceased
- 2011-11-11 AU AU2011325982A patent/AU2011325982C1/en not_active Ceased
- 2011-11-11 JP JP2013538939A patent/JP2013542264A/ja active Pending
- 2011-11-11 SG SG2013036280A patent/SG190244A1/en unknown
- 2011-11-11 EP EP11840607.3A patent/EP2638397A4/en not_active Withdrawn
- 2011-11-11 EA EA201390694A patent/EA025069B1/ru not_active IP Right Cessation
- 2011-11-11 WO PCT/US2011/060395 patent/WO2012065079A1/en not_active Ceased
- 2011-11-11 SG SG2013036306A patent/SG190245A1/en unknown
- 2011-11-11 BR BR112013011659A patent/BR112013011659A2/pt not_active IP Right Cessation
- 2011-11-11 US US13/884,842 patent/US8883737B2/en not_active Expired - Fee Related
- 2011-11-11 MX MX2013005196A patent/MX2013005196A/es unknown
- 2011-11-11 CN CN201180061415.4A patent/CN103403552B/zh not_active Expired - Fee Related
- 2011-11-11 CA CA2817219A patent/CA2817219A1/en not_active Abandoned
- 2011-11-11 MX MX2013005194A patent/MX2013005194A/es unknown
-
2013
- 2013-03-13 US US13/800,254 patent/US20140066383A1/en not_active Abandoned
- 2013-05-09 IL IL226247A patent/IL226247A0/en unknown
- 2013-05-09 IL IL226246A patent/IL226246A0/en unknown
- 2013-05-13 CL CL2013001324A patent/CL2013001324A1/es unknown
- 2013-05-13 CL CL2013001322A patent/CL2013001322A1/es unknown
- 2013-06-10 ZA ZA2013/04226A patent/ZA201304226B/en unknown
- 2013-06-10 ZA ZA2013/04225A patent/ZA201304225B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2011325989B2 (en) | Methods of treating cancer | |
| EP2786756B1 (en) | Combination therapy with a topoisomerase inhibitor | |
| US20110052580A1 (en) | Use of picoplatin and bevacizumab to treat colorectal cancer | |
| US20170232017A1 (en) | Treatment of cancer | |
| TWI469776B (zh) | 有助於癌症之治療的方法，組成物以及製品 | |
| AU2019233338B2 (en) | Antitumor agent, antitumor effect potentiator and antitumor kit | |
| US20130252904A1 (en) | Compositions and methods for treating cancer | |
| KR101847252B1 (ko) | 이리노테칸염산염 수화물을 함유하는 항종양제 | |
| AU2013204338A1 (en) | Methods of treating cancer | |
| AU2013204342A1 (en) | Methods of treating cancer | |
| HK1189057A (en) | Methods of treating cancer | |
| HK1189272B (en) | Methods of treating cancer | |
| HK1202423B (en) | Combination therapy with a topoisomerase inhibitor | |
| HK1202419B (en) | Combination therapy with a mitotic inhibitor | |
| WO2011152515A1 (ja) | インドール化合物を含有する抗腫瘍剤 |